Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase 2
Completed
- Conditions
- MelanomaNeoplasm Metastasis
- Interventions
- Drug: IL-2Procedure: ApheresisBiological: Abl cellsDrug: Montanide ISA-51Drug: FludarabineDrug: CyclophosphamideBiological: GCSF (Growth colony stimulating factor)
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 170
- Registration Number
- NCT00001832
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
Phase 1
Completed
- Conditions
- Sickle Cell Anemia
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00004485
- Locations
- 🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath